Position of the Transparency Council – Forxiga (dapagliflozin)
At its meeting on 20 January 2025, the Transparency Council adopted position No. 7/2025 on the evaluation of the drug Forxiga (dapagliflozin) for the indication: type 2 diabetes.
At its meeting on 20 January 2025, the Transparency Council adopted position No. 7/2025 on the evaluation of the drug Forxiga (dapagliflozin) for the indication: type 2 diabetes.